Speciality Medical Dialogues
    • facebook
    • twitter
    Login Register
    • facebook
    • twitter
    Login Register
    • Medical Dialogues
    • Education Dialogues
    • Business Dialogues
    • Medical Jobs
    • Medical Matrimony
    • MD Brand Connect
    Speciality Medical Dialogues
    • Editorial
    • News
        • Anesthesiology
        • Cancer
        • Cardiac Sciences
        • Critical Care
        • Dentistry
        • Dermatology
        • Diabetes and Endo
        • Diagnostics
        • ENT
        • Featured Research
        • Gastroenterology
        • Geriatrics
        • Medicine
        • Nephrology
        • Neurosciences
        • Nursing
        • Obs and Gynae
        • Ophthalmology
        • Orthopaedics
        • Paediatrics
        • Parmedics
        • Pharmacy
        • Psychiatry
        • Pulmonology
        • Radiology
        • Surgery
        • Urology
    • Practice Guidelines
        • Anesthesiology Guidelines
        • Cancer Guidelines
        • Cardiac Sciences Guidelines
        • Critical Care Guidelines
        • Dentistry Guidelines
        • Dermatology Guidelines
        • Diabetes and Endo Guidelines
        • Diagnostics Guidelines
        • ENT Guidelines
        • Featured Practice Guidelines
        • Gastroenterology Guidelines
        • Geriatrics Guidelines
        • Medicine Guidelines
        • Nephrology Guidelines
        • Neurosciences Guidelines
        • Obs and Gynae Guidelines
        • Ophthalmology Guidelines
        • Orthopaedics Guidelines
        • Paediatrics Guidelines
        • Psychiatry Guidelines
        • Pulmonology Guidelines
        • Radiology Guidelines
        • Surgery Guidelines
        • Urology Guidelines
    LoginRegister
    Speciality Medical Dialogues
    LoginRegister
    • Home
    • Editorial
    • News
      • Anesthesiology
      • Cancer
      • Cardiac Sciences
      • Critical Care
      • Dentistry
      • Dermatology
      • Diabetes and Endo
      • Diagnostics
      • ENT
      • Featured Research
      • Gastroenterology
      • Geriatrics
      • Medicine
      • Nephrology
      • Neurosciences
      • Nursing
      • Obs and Gynae
      • Ophthalmology
      • Orthopaedics
      • Paediatrics
      • Parmedics
      • Pharmacy
      • Psychiatry
      • Pulmonology
      • Radiology
      • Surgery
      • Urology
    • Practice Guidelines
      • Anesthesiology Guidelines
      • Cancer Guidelines
      • Cardiac Sciences Guidelines
      • Critical Care Guidelines
      • Dentistry Guidelines
      • Dermatology Guidelines
      • Diabetes and Endo Guidelines
      • Diagnostics Guidelines
      • ENT Guidelines
      • Featured Practice Guidelines
      • Gastroenterology Guidelines
      • Geriatrics Guidelines
      • Medicine Guidelines
      • Nephrology Guidelines
      • Neurosciences Guidelines
      • Obs and Gynae Guidelines
      • Ophthalmology Guidelines
      • Orthopaedics Guidelines
      • Paediatrics Guidelines
      • Psychiatry Guidelines
      • Pulmonology Guidelines
      • Radiology Guidelines
      • Surgery Guidelines
      • Urology Guidelines
    • Home
    • News
    • Cardiac Sciences
    • Concomitant...

    Concomitant methotrexate, bDMARDs use reduces CVD risk in RA

    Written by Vinay Singh singh Published On 2018-11-06T19:05:10+05:30  |  Updated On 6 Nov 2018 7:05 PM IST
    Concomitant methotrexate, bDMARDs use reduces CVD risk in RA

    Patients with rheumatoid arthritis (RA) receiving concomitant therapy with methotrexate (MTX) and biologic disease-modifying antirheumatic drugs (bDMARDs) were reported to have reduced risk for cardiovascular disease (CVD).


    The findings of the study presented at the 2018 ACR/ARHP Annual Meeting, held in Chicago, reveals that an overall 23% reduction of CVD risk is associated with concomitant MTX use.


    Read Also: Whole-fat dairy provides protection from cardiovascular disease and mortality : Lancet


    Fenglong Xie and associates conducted a retrospective cohort study using 2006-2015 Medicare claims data for RA patients.Follow-up commenced at initiation (index date) and concluded at the earliest occurrence of 1 of the following: (1) end of exposure of the specific bDMARD (days of supply with 90-day extension); (2) switch to another bDMARD or to tofacitinib; (3) CVD event; (4) death date; (5) loss of Medicare coverage; or (6) end of study.


    MTX use was defined as follows: (1) concomitant MTX use, with a prescription for MTX within 120 days after the index date and (2) time-varying MTX, which denoted prescription date to prescription date plus days of supply without extension. A 90-day extension was added to days of supply, for sensitivity analysis. The primary study outcome was the composite of incident myocardial infarction, incident stroke, and fatal CVD.


    A total of 88,255 DMARDS initiations (64,218 patients) were included in the study with a median age at initiation 64.6 years.


    Read Also: Some rheumatoid arthritis Treatments linked to Improvement in BP



    The key study findings included are:




    • The crude incidence ratios (IRs) for CVD were 13.1 and 18.7 events per 1,000 person-years (PY) for RA patients with and without concomitant MTX respectively.

    • The crude IRs for CVD were 12.1 and 17.9 events per 1,000 PY for RA patients with and without time-varying MTX respectively.

    • P-value for interaction between concomitant MTX and background bDMARDS was 0.0189 and p-value for interaction between time-varying MTX and background bDMARDS was 0.0030.

    • The contrast HRs for concomitant MTX ranged from 0.61 for golimumab initiators to 0.97 for adalimumab initiators.

    • The contrast HRs for time-varying MTX ranged from 0.58 for certolizumab initiators to 0.90 for adalimumab initiators.


    “Our observational study suggests an overall 23% reduction of CVD risk associated with concomitant MTX use. The effect sizes vary among background bDMARDS, ”write the authors.


    For reference log on to


    https://acrabstracts.org/abstract/methotrexate-use-and-the-risk-for-cardiovascular-disease-among-rheumatoid-patients-initiating-biologic-disease-modifying-anti-rheumatic-drugs/


    biologiccardiovascularconcomitantCVDdiseasemeetingMethotrexatemodifyingrheumatoidrisktherapyupdates
    Source : With inputs from ACR/ARHP Annual Meeting

    Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd

    Vinay Singh singh
    Vinay Singh singh
      Show Full Article
      Next Story
      Similar Posts
      NO DATA FOUND

      • Email: info@medicaldialogues.in
      • Phone: 011 - 4372 0751

      Website Last Updated On : 12 Oct 2022 7:06 AM GMT
      Company
      • About Us
      • Contact Us
      • Our Team
      • Reach our Editor
      • Feedback
      • Submit Article
      Ads & Legal
      • Advertise
      • Advertise Policy
      • Terms and Conditions
      • Privacy Policy
      • Editorial Policy
      • Comments Policy
      • Disclamier
      Medical Dialogues is health news portal designed to update medical and healthcare professionals but does not limit/block other interested parties from accessing our general health content. The health content on Medical Dialogues and its subdomains is created and/or edited by our expert team, that includes doctors, healthcare researchers and scientific writers, who review all medical information to keep them in line with the latest evidence-based medical information and accepted health guidelines by established medical organisations of the world.

      Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription.Use of this site is subject to our terms of use, privacy policy, advertisement policy. You can check out disclaimers here. © 2025 Minerva Medical Treatment Pvt Ltd

      © 2025 - Medical Dialogues. All Rights Reserved.
      Powered By: Hocalwire
      X
      We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok